GlassScriptPhysician profile
Beth A Horseman
NPI 1316507205
$2,530.67
in general payments reported to CMS, 2019-2025
36 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $675 · 2023: $503 · 2024: $461 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,257.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $599.71 | 2021-2025 | |
| Lilly USA, LLC | $312.44 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $128.27 | 2022 | |
| Novo Nordisk INC | $117.69 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $99.74 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $84.07 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $82.63 | 2021-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $80.43 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.89 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.16 | 2023-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $68.80 | 2022-2024 | Farxiga, Airsupra |
| Amgen INC. | $67.80 | 2021-2024 | Repatha, Otezla |
| Pfizer INC. | $67.52 | 2024-2025 | |
| Abbott Laboratories | $64.59 | 2021-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $58.99 | 2021-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Horseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.